← Back to federal legislation
H.R. 950In committee

Saving Seniors Money on Prescriptions Act

Introduced: Feb 4, 2025

Latest action date: Feb 4, 2025

Latest development

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Your view
Congress
119th Congress
Introduced
Feb 4, 2025
Recorded roll calls
0

Status detail: The most advanced recorded stage is committee consideration.

Plain-language overview

What this bill does

Saving Seniors Money on Prescriptions Act

This bill establishes reporting requirements for pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs.

Specifically, PBMs must (1) disclose certain information underlying cost performance measurements (e.g., exclusions and terms), and (2) report to prescription drug plan (PDP) sponsors (and to the Centers for Medicare & Medicaid Services upon request) an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with this bill's requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations.

In addition, the Government Accountability Office must study federal and state reporting requirements for health plans and PBMs with respect to prescription drug price transparency and recommend ways to streamline these requirements.

Civixly topics

What this legislation is about

Civixly topics make federal and state legislation comparable. They are derived from the official CRS policy area and legislative subjects.

Official CRS policy area

Health

View 9 official legislative subjects
Accounting and auditingCongressional oversightContracts and agencyDrug safety, medical device, and laboratory regulationGovernment information and archivesGovernment studies and investigationsHealth care costs and insurancePrescription drugsRetail and wholesale trades

Committee activity

Committees and subcommittees that received, reviewed, marked up, or reported this legislation.

Amendments

Proposed changes to this measure, with their latest official outcome or action from Congress.gov.

No amendments are listed for this measure.

Checked against Congress.gov Sep 14, 2026.

Action timeline

Newest action first. Action language comes from the official Congress.gov record.

View full action timeline3 actions
  1. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    IntroReferralHouse floor actions
  2. Introduced in House

    IntroReferralLibrary of Congress
  3. Introduced in House

    IntroReferralLibrary of Congress

Roll-call votes

Recorded House and Senate votes connected to this bill. Your representatives appear first when available.

No connected roll-call votes are currently available for this bill.

Discussion

0 comments

Sign in to join the discussion.Comments are publicly visible.

Loading comments...

Sources: Congress.gov and official House and Senate vote records.

View data freshness details

Base metadata check pending · Summary check pending · Action timeline checked Sep 14, 2026 · Complete sponsorship check pending · Topics checked Sep 14, 2026 · Committees checked Sep 14, 2026 · Status checked Sep 14, 2026 · Related bills checked Sep 14, 2026.